Apontis Pharma AG (FRA:APPH) Selling, General, & Admin. Expense: €6.46 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:APPH Apontis Pharma AG FRA:APPH
17 GF Score
Price €11.00
GF Value €10.46
! 7 Warning Signs
View Full Analysis

What is Apontis Pharma AG Selling, General, & Admin. Expense?

Apontis Pharma AG FRA:APPH 17 Selling, General, & Admin. Expense is €6.46 Mil as of Jun. 2025. GuruFocus rates FRA:APPH with a GF Score™ of 17/100 and a GF Value™ of €10.46. The stock has 7 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Apontis Pharma AG's selling, general, & admin. expense for the six months ended in Jun. 2025 was €4.55 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2025 was €6.46 Mil.


Apontis Pharma AG  (FRA:APPH) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Apontis Pharma AG Selling, General, & Admin. Expense Related Terms


Apontis Pharma AG Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Apontis Pharma AG's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apontis Pharma AG Selling, General, & Admin. Expense Chart

Apontis Pharma AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 5.63 6.24 6.89 6.41 5.50

Apontis Pharma AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.91 2.51 3.60 1.90 4.55

FRA:APPH vs ZTS, UTHR, NBIX: Selling, General, & Admin. Expense Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apontis Pharma AG Selling, General, & Admin. Expense vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Apontis Pharma AG's Selling, General, & Admin. Expense falls into.


FRA:APPH
17GF Score
Apontis Pharma AG FRA:APPH
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apontis Pharma AG Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €6.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of €6.46 Mil mean?
Apontis Pharma AG (FRA:APPH) has a Selling, General, & Admin. Expense of €6.46 Mil as of Jun. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Apontis Pharma AG and its competitors.
Is Apontis Pharma AG's Selling, General, & Admin. Expense too high?
Apontis Pharma AG's current Selling, General, & Admin. Expense is €6.46 Mil. Overall, Apontis Pharma AG has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Apontis Pharma AG's Selling, General, & Admin. Expense compare to ZTS and UTHR?
Apontis Pharma AG's Selling, General, & Admin. Expense of €6.46 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Apontis Pharma AG and its competitors. Apontis Pharma AG's current Selling, General, & Admin. Expense is €6.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apontis Pharma AG stock overvalued right now?
Apontis Pharma AG (FRA:APPH) has a current Selling, General, & Admin. Expense of €6.46 Mil. The stock's GF Value™ is €10.46, compared to a current price of €11.00 — trading 5.2% above its estimated fair value. The current Selling, General, & Admin. Expense is €6.46 Mil. Apontis Pharma AG's overall GF Score™ is 17/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Apontis Pharma AG (FRA:APPH), the current Selling, General, & Admin. Expense is €6.46 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?

Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued. The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.

Key valuation signals for FRA:APPH:

  • Selling, General, & Admin. Expense: €6.46 Mil
  • GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
  • GF Score™: 17/100 with 7 warning signs

No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Apontis Pharma AG Business Description

Address Rolf-Schwarz-Schutte-Platz 1, Monheim, BY, DEU, 40789
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score

Get the complete analysis for FRA:APPH

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.00
Price
€10.46
GF Value